CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Mainz Biomed (MYNZ) shares double since IPO

By Jenny McCall

13:00, 12 November 2021

AI smart healthcare technology concept
AI smart healthcare technology concept – Photo: Shutterstock.

Mainz BioMed (MYNZ) opened higher Friday on the Nasdaq, addng 5% to $9.90 per share. Since listing on the stock exchange last week Friday, shares have reached as high as $18 per share.

The company located just west of Frankfurt, Germany on 4 November priced an initial public offering (IPO) of 2 million shares at $5.00. Shares have been trading above that price since the IPO and rose over 9% yesterday, closing at $9.39.

Investors are apparently keen on Mainz Biomed, a molecular genetics cancer diagnostic company, which can predict serious conditions in people before they even arise, and all based on the individuals’ genetics. caught up with Mainz BioMed to discuss its current growth and future ambitions.

Critical milestone

Guido Baechler, the CEO of Mainz BioMed, raised £10m for its IPO and said this period is a giant leap for the company and a critical “milestone.”

“Transitioning to the public markets via a Nasdaq listing is an important milestone for the company, as it provides a platform to facilitate growth, and to ultimately execute on our mission to become a leader in developing next generation early detection diagnostics for multiple cancer indications,” Baechler, told

Early detection of Cancer

The company said it intends to use the funds from the IPO on research and development – improving its flagship product, ColoAlert, a cancer early detection test and launching clinical studies for US Food and Drug Administration (FDA) premarket approval (PMA), as well as sales and marketing in the European market


235.62 Price
-0.320% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.12


6.64 Price
-2.360% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.03


0.70 Price
-1.270% 1D Chg, %
Long position overnight fee -0.0253%
Short position overnight fee 0.0033%
Overnight fee time 22:00 (UTC)
Spread 0.0025


477.97 Price
-1.000% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.18

So, what about market expansion and growth? Mainz BioMed believes Europe is key for them right now.

“Mainz BioMed’s main market is Europe and other countries where our CE labelled product is approved for sale. With our company located in Mainz, Germany, we will leverage our experience in that market in other European markets,” Baechler added.

However the company still intends to expand outside of Germany, into other European countries followed by outside of the EU. Mainz Biomed believes that this will allow ColoAlert to be sold as a CE marked product. A future milestone will be the US market which, Mainz BioMed said it will start commercialisation after it receives approval from the FDA.

Life changing technology

With an innovative product pipeline and technology that helps detect life threatening illnesses before they even arise, Mainz BioMed has an important role to play in the industry.

“Early cancer detection is a fast-growing market for many different cancers. We believe that we will be able to leverage our success in the early detection of CRC and expand as we progress with our business plan,” Baechler, told

“We do not plan to publicly forecast our financial results. We believe that the market opportunity is vast and intend to target growth as quickly as possible,” Baechler added.

The company said its at the early stages in research to develop an early pancreatic cancer test called PancAlert.

Read more: Novartis acquires gene therapy firm Arctos Medical

Related topics

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading